Kurosaki M - Search Results

1

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.

Tsuchiya K, Kurosaki M, Sakamoto A, Marusawa H, Kojima Y, Hasebe C, Arai H, Joko K, Kondo M, Tsuji K, Sohda T, Kimura H, Ogawa C, Uchida Y, Wada S, Kobashi H, Furuta K, Shigeno M, Kusakabe A, Akahane T, Narita R, Yoshida H, Mitsuda A, Ide Y, Matsushita T, Izumi N, On Behalf Of Japanese Red Cross Liver Study Group. Tsuchiya K, et al. Among authors: kurosaki m. Cancers (Basel). 2021 May 26;13(11):2608. doi: 10.3390/cancers13112608. Cancers (Basel). 2021. PMID: 34073396 Free PMC article.

2

Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment.

Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C. Koizumi K, et al. Among authors: kurosaki m. Hepatology. 1995 Jul;22(1):30-5. Hepatology. 1995. PMID: 7541387

3

A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.

Izumi N, Asahina Y, Kurosaki M, Uchihara M, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Hamano K, Itakura J, Miyake S. Izumi N, et al. Among authors: kurosaki m. Intervirology. 2004;47(2):102-7. doi: 10.1159/000077833. Intervirology. 2004. PMID: 15192274 Clinical Trial.

4

Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.

Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H, Tsuchiya K, Hamano K, Asahina Y, Kurosaki M, Uchihara M, Miyake S. Itakura J, et al. Among authors: kurosaki m. Hepatol Res. 2004 Aug;29(4):216-222. doi: 10.1016/j.hepres.2004.04.001. Hepatol Res. 2004. PMID: 15288014

5

[Analysis of replicating hepatitis C virus quasispecies in hepatocellular carcinoma tissues].

Kurosaki M, Izumi N, Enomoto N. Kurosaki M, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):624-8. Nihon Rinsho. 2004. PMID: 15359873 Review. Japanese. No abstract available.

6

Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?

Izumi N, Yasuhiro A, Kurosaki M, Onuki Y, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Nakanishi H, Uchihara M, Miyake S. Izumi N, et al. Among authors: kurosaki m. Intervirology. 2005;48(1):59-63. doi: 10.1159/000082096. Intervirology. 2005. PMID: 15785091

7

Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy.

Tanabe Y, Nagayama K, Enomoto N, Izumi N, Tazawa J, Kurosaki M, Sakamoto N, Sato C, Watanabe M. Tanabe Y, et al. Among authors: kurosaki m. J Viral Hepat. 2005 May;12(3):251-61. doi: 10.1111/j.1365-2893.2005.00511.x. J Viral Hepat. 2005. PMID: 15850465

8

Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.

Nakanishi H, Kurosaki M, Asahina Y, Onuki Y, Ueda K, Nishimura Y, Tsuchiya K, Kitamura T, Uchihara M, Miyake S, Enomoto N, Izumi N. Nakanishi H, et al. Among authors: kurosaki m. Intervirology. 2005;48(6):381-8. doi: 10.1159/000086065. Intervirology. 2005. PMID: 16024942

9

Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.

Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S. Asahina Y, et al. Among authors: kurosaki m. J Hepatol. 2005 Oct;43(4):623-9. doi: 10.1016/j.jhep.2005.05.032. J Hepatol. 2005. PMID: 16098627

10

Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy.

Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, Ueda E, Tanabe Y, Maekawa S, Itakura J, Watanabe H, Kakinuma S, Watanabe M. Hamano K, et al. Among authors: kurosaki m. J Gastroenterol Hepatol. 2005 Sep;20(9):1401-9. doi: 10.1111/j.1440-1746.2005.04024.x. J Gastroenterol Hepatol. 2005. PMID: 16105128

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

501 results

Search Page